Nathan A. Pennell, MD, PhD


Treating ALK-Positive Lung Cancer in the Weeks After the FDA Approval of Crizotinib

May 10, 2012

As physicians enter a new world of therapies for molecularly defined lung cancer, it will be critical for hospitals, drug companies, and insurance companies to work out the interplay of molecular testing and coverage for expensive therapies that are effective but only in smaller, defined groups of patients.